(CLBT) Cellebrite DI - Overview
Exchange: NASDAQ •
Country: Israel •
Currency: USD •
Type: Common Stock •
ISIN: IL0011794802
Stock: Digital Forensics, Data Analysis, Intelligence Tools, Case Management
Total Rating 32
Risk 67
Buy Signal -0.77
| Risk 5d forecast | |
|---|---|
| Volatility | 46.5% |
| Relative Tail Risk | -13.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.48 |
| Alpha | -37.67 |
| Character TTM | |
|---|---|
| Beta | 0.724 |
| Beta Downside | 0.191 |
| Drawdowns 3y | |
|---|---|
| Max DD | 54.08% |
| CAGR/Max DD | 0.65 |
EPS (Earnings per Share)
Revenue
Description: CLBT Cellebrite DI March 05, 2026
Cellebrite DI Ltd. (CLBT) provides digital intelligence solutions for legally sanctioned investigations globally. The companys software suite facilitates the access, collection, analysis, and management of digital data across various case types, including child exploitation, homicide, and anti-terrorism.
Cellebrites business model focuses on selling specialized software and services to government agencies, including federal, state, and local entities. This B2G (business-to-government) model often involves long sales cycles but can result in stable, recurring revenue streams due to the critical nature of the services provided. The digital forensics sector, in which Cellebrite operates, is characterized by evolving technological demands and a constant need for updated tools to address new digital evidence sources and encryption methods.
Key products include Inseyets for digital evidence collection, Cellebrite Pathfinder for automated data analysis, and Guardian for case management. The company also offers professional services like training and certification.
To gain a deeper understanding of Cellebrites market position and financial health, further research on ValueRay is recommended.
Headlines to watch out for
- Government budget allocations impact digital forensics spending
- Law enforcement demand drives software license renewals
- Data privacy regulations influence product development
- Cybersecurity threats increase investigative tool adoption
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 78.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA -1.02 > 1.0 |
| NWC/Revenue: 43.35% < 20% (prev 67.82%; Δ -24.47% < -1%) |
| CFO/TA 0.18 > 3% & CFO 169.0m > Net Income 78.3m |
| Net Debt (-101.8m) to EBITDA (83.6m): -1.22 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (251.5m) vs 12m ago 1.68% < -2% |
| Gross Margin: 84.20% > 18% (prev 0.84%; Δ 8.34k% > 0.5%) |
| Asset Turnover: 58.39% > 50% (prev 58.10%; Δ 0.29% > 0%) |
| Interest Coverage Ratio: 137.2 > 6 (EBITDA TTM 83.6m / Interest Expense TTM 523k) |
Altman Z'' 1.54
| A: 0.22 (Total Current Assets 575.9m - Total Current Liabilities 369.7m) / Total Assets 938.9m |
| B: -0.09 (Retained Earnings -86.5m / Total Assets 938.9m) |
| C: 0.09 (EBIT TTM 71.8m / Avg Total Assets 814.7m) |
| D: -0.19 (Book Value of Equity -84.3m / Total Liabilities 454.5m) |
| Altman-Z'' Score: 1.54 = BB |
Beneish M -2.04
| DSRI: 1.08 (Receivables 105.0m/82.4m, Revenue 475.7m/401.2m) |
| GMI: 1.00 (GM 84.20% / 84.40%) |
| AQI: 2.50 (AQ_t 0.35 / AQ_t-1 0.14) |
| SGI: 1.19 (Revenue 475.7m / 401.2m) |
| TATA: -0.10 (NI 78.3m - CFO 169.0m) / TA 938.9m) |
| Beneish M-Score: -2.04 (Cap -4..+1) = BB |
What is the price of CLBT shares?
As of March 22, 2026, the stock is trading at USD 14.27 with a total of 3,359,300 shares traded.
Over the past week, the price has changed by -1.18%, over one month by +8.43%, over three months by -25.83% and over the past year by -25.05%.
Over the past week, the price has changed by -1.18%, over one month by +8.43%, over three months by -25.83% and over the past year by -25.05%.
Is CLBT a buy, sell or hold?
Cellebrite DI has received a consensus analysts rating of 4.75.
Therefore, it is recommended to buy CLBT.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.7 | 51.9% |
| Analysts Target Price | 21.7 | 51.9% |
CLBT Fundamental Data Overview March 21, 2026
P/E Trailing = 47.871
P/E Forward = 35.7143
P/S = 7.782
P/B = 7.5092
Revenue TTM = 475.7m USD
EBIT TTM = 71.8m USD
EBITDA TTM = 83.6m USD
Long Term Debt = 22.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.00m USD (from shortTermDebt, last quarter)
Debt = 22.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -101.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.29b USD (3.70b + Debt 22.7m - CCE 437.1m)
Interest Coverage Ratio = 137.2 (Ebit TTM 71.8m / Interest Expense TTM 523k)
EV/FCF = 21.11x (Enterprise Value 3.29b / FCF TTM 155.7m)
FCF Yield = 4.74% (FCF TTM 155.7m / Enterprise Value 3.29b)
FCF Margin = 32.74% (FCF TTM 155.7m / Revenue TTM 475.7m)
Net Margin = 16.47% (Net Income TTM 78.3m / Revenue TTM 475.7m)
Gross Margin = 84.20% ((Revenue TTM 475.7m - Cost of Revenue TTM 75.2m) / Revenue TTM)
Gross Margin QoQ = 84.71% (prev 83.88%)
Tobins Q-Ratio = 3.50 (Enterprise Value 3.29b / Total Assets 938.9m)
Interest Expense / Debt = 2.31% (Interest Expense 523k / Debt 22.7m)
Taxrate = 19.07% (5.01m / 26.3m)
NOPAT = 58.1m (EBIT 71.8m * (1 - 19.07%))
Current Ratio = 1.56 (Total Current Assets 575.9m / Total Current Liabilities 369.7m)
Debt / Equity = 0.05 (Debt 22.7m / totalStockholderEquity, last quarter 484.3m)
Debt / EBITDA = -1.22 (Net Debt -101.8m / EBITDA 83.6m)
Debt / FCF = -0.65 (Net Debt -101.8m / FCF TTM 155.7m)
Total Stockholder Equity = 426.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.61% (Net Income 78.3m / Total Assets 938.9m)
RoE = 18.39% (Net Income TTM 78.3m / Total Stockholder Equity 426.0m)
RoCE = 16.00% (EBIT 71.8m / Capital Employed (Equity 426.0m + L.T.Debt 22.7m))
RoIC = 13.64% (NOPAT 58.1m / Invested Capital 426.0m)
WACC = 8.54% (E(3.70b)/V(3.72b) * Re(8.58%) + D(22.7m)/V(3.72b) * Rd(2.31%) * (1-Tc(0.19)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.73%
[DCF] Terminal Value 79.53% ; FCFF base≈142.1m ; Y1≈175.2m ; Y5≈298.5m
[DCF] Fair Price = 18.63 (EV 4.55b - Net Debt -101.8m = Equity 4.65b / Shares 249.4m; r=8.54% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 57.85 | EPS CAGR: 74.11% | SUE: -0.43 | # QB: 0
Revenue Correlation: 98.70 | Revenue CAGR: 21.33% | SUE: 0.99 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.12 | Chg7d=-0.009 | Chg30d=-0.025 | Revisions Net=+0 | Analysts=6
EPS current Year (2026-12-31): EPS=0.53 | Chg7d=-0.008 | Chg30d=-0.008 | Revisions Net=+0 | Growth EPS=+4.0% | Growth Revenue=+19.4%
EPS next Year (2027-12-31): EPS=0.61 | Chg7d=-0.065 | Chg30d=-0.065 | Revisions Net=+1 | Growth EPS=+15.0% | Growth Revenue=+16.9%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.5% (Discount Rate 8.6% - Earnings Yield 2.1%)
[Growth] Growth Spread = +12.5% (Analyst 19.0% - Implied 6.5%)
P/E Forward = 35.7143
P/S = 7.782
P/B = 7.5092
Revenue TTM = 475.7m USD
EBIT TTM = 71.8m USD
EBITDA TTM = 83.6m USD
Long Term Debt = 22.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.00m USD (from shortTermDebt, last quarter)
Debt = 22.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -101.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.29b USD (3.70b + Debt 22.7m - CCE 437.1m)
Interest Coverage Ratio = 137.2 (Ebit TTM 71.8m / Interest Expense TTM 523k)
EV/FCF = 21.11x (Enterprise Value 3.29b / FCF TTM 155.7m)
FCF Yield = 4.74% (FCF TTM 155.7m / Enterprise Value 3.29b)
FCF Margin = 32.74% (FCF TTM 155.7m / Revenue TTM 475.7m)
Net Margin = 16.47% (Net Income TTM 78.3m / Revenue TTM 475.7m)
Gross Margin = 84.20% ((Revenue TTM 475.7m - Cost of Revenue TTM 75.2m) / Revenue TTM)
Gross Margin QoQ = 84.71% (prev 83.88%)
Tobins Q-Ratio = 3.50 (Enterprise Value 3.29b / Total Assets 938.9m)
Interest Expense / Debt = 2.31% (Interest Expense 523k / Debt 22.7m)
Taxrate = 19.07% (5.01m / 26.3m)
NOPAT = 58.1m (EBIT 71.8m * (1 - 19.07%))
Current Ratio = 1.56 (Total Current Assets 575.9m / Total Current Liabilities 369.7m)
Debt / Equity = 0.05 (Debt 22.7m / totalStockholderEquity, last quarter 484.3m)
Debt / EBITDA = -1.22 (Net Debt -101.8m / EBITDA 83.6m)
Debt / FCF = -0.65 (Net Debt -101.8m / FCF TTM 155.7m)
Total Stockholder Equity = 426.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.61% (Net Income 78.3m / Total Assets 938.9m)
RoE = 18.39% (Net Income TTM 78.3m / Total Stockholder Equity 426.0m)
RoCE = 16.00% (EBIT 71.8m / Capital Employed (Equity 426.0m + L.T.Debt 22.7m))
RoIC = 13.64% (NOPAT 58.1m / Invested Capital 426.0m)
WACC = 8.54% (E(3.70b)/V(3.72b) * Re(8.58%) + D(22.7m)/V(3.72b) * Rd(2.31%) * (1-Tc(0.19)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.73%
[DCF] Terminal Value 79.53% ; FCFF base≈142.1m ; Y1≈175.2m ; Y5≈298.5m
[DCF] Fair Price = 18.63 (EV 4.55b - Net Debt -101.8m = Equity 4.65b / Shares 249.4m; r=8.54% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 57.85 | EPS CAGR: 74.11% | SUE: -0.43 | # QB: 0
Revenue Correlation: 98.70 | Revenue CAGR: 21.33% | SUE: 0.99 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.12 | Chg7d=-0.009 | Chg30d=-0.025 | Revisions Net=+0 | Analysts=6
EPS current Year (2026-12-31): EPS=0.53 | Chg7d=-0.008 | Chg30d=-0.008 | Revisions Net=+0 | Growth EPS=+4.0% | Growth Revenue=+19.4%
EPS next Year (2027-12-31): EPS=0.61 | Chg7d=-0.065 | Chg30d=-0.065 | Revisions Net=+1 | Growth EPS=+15.0% | Growth Revenue=+16.9%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.5% (Discount Rate 8.6% - Earnings Yield 2.1%)
[Growth] Growth Spread = +12.5% (Analyst 19.0% - Implied 6.5%)